Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial-Reference-Cited by-同舟云学术

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

Published:2015-10 Issue:10 Volume:15 Page:1167-1174
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Koh Christopher,Canini Laetitia,Dahari Harel,Zhao Xiongce,Uprichard Susan L,Haynes-Williams Vanessa,Winters Mark A,Subramanya Gitanjali,Cooper Stewart L,Pinto Peter,Wolff Erin F,Bishop Rachel,Ai Thanda Han Ma,Cotler Scott J,Kleiner David E,Keskin Onur,Idilman Ramazan,Yurdaydin Cihan,Glenn Jeffrey S,Heller Theo

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

National Cancer Institute, National Institutes of Health

Eiger Biopharmaceuticals Inc

Intramural Research Programs of the National Institute of Diabetes and Digestive and Kidney Diseases

National Cancer Institute (NCI) of the National Institutes of Health

NIH

US Department of Energy

Publisher

Elsevier BV

Subject

Infectious Diseases